Chengdu Ucello Biotechnology Co., Ltd.

This early-stage study is testing a new cell therapy called CD19/BCMA CAR-T for adults with severe lupus that hasn't responded to standard treatments. The main goals are to find the safest and most effective dose and to see if the therapy can reduce lupus disease activity, potent…

This early-stage study is testing a new type of personalized cell therapy for adults with advanced solid tumors that have a specific marker called Claudin18.2. The main goals are to see if the treatment is safe and if it can shrink tumors. Participants will have their own immune …